Lee Howard 4

What Happened
Lee Howard, a director of Amphastar Pharmaceuticals (AMPH), received equity awards on June 1, 2026: 8,143 restricted stock units (RSUs) and 17,365 shares from a derivative award (e.g., option-type award). Both grants were reported at $0 per share (award/grant). On June 2, 2026, 769 shares were withheld/disposed to cover tax withholding at $18.45 per share, totaling $14,188. These transactions are awards (A) and a tax-withholding disposition (F), not open-market purchases or sales.

Key Details

• Transaction dates and prices:
  • 2026-06-01: Award of 8,143 shares (RSUs) at $0.00 (acquired).
  • 2026-06-01: Award of 17,365 derivative shares at $0.00 (acquired).
  • 2026-06-02: 769 shares withheld/disposed at $18.45 to satisfy tax liability (proceeds $14,188).
• Net change: 25,508 shares granted minus 769 shares withheld = net increase of 24,739 shares reported.
• Vesting/footnotes:
  • F1: The RSUs vest on June 1, 2027.
  • F3: The derivative/option-type award vests on June 1, 2027.
  • F2: The 769-share disposition was a withholding to satisfy tax obligations related to the vesting.
• Filing timeliness: Form 4 filed 2026-06-03 appears timely (transactions on 06-01 and 06-02).

Context

• These were equity awards (grants/RSUs and a derivative award) rather than open-market purchases or voluntary sales. The withheld 769 shares reflect routine tax withholding (a cashless-to-cover event) and should not be interpreted the same way as an intentional sale for investment reasons.
• The awards vest on June 1, 2027, so the shares are subject to future vesting conditions rather than immediate free-trading shares.